Exosens stock declines nearly 2% despite Q3 up 23.5%
The Bordeaux-based group is retreating mid-morning, in a quasi-stable SBF 120. The decline follows strong quarterly revenue growth and extends a series of downward-oriented sessions.
A stock below all its moving averages, at 55.75 €
Exosens stock loses 1.85% to 55.75 € in trading, placing it among the strongest declines of the SBF 120 while the index remains stable. Over one month, the decline reaches 10.51%.
The price is below its 20-day MA (gap of -3.60%), its 50-day MA (-4.64%) and its 200-day MA (-7.51%). It is approaching the 54.35 € support level, approximately 2.5% below the current level, while the RSI at 42 remains neutral.
Today's decline adds to a downward trend established for several weeks, without the stock having recovered its 20-day MA since the beginning of the month.
A third quarter in acceleration, with gross margin in decline
On October 27, Exosens reported revenue of 133.8 million € in the third quarter, up 23.5%. At constant scope and exchange rates, growth reaches 20.5%, compared to 11.4% in the first half. The adjusted gross margin rate, however, fell to 48.6%, compared to 52.1% a year earlier, which the group attributes to product mix effects.
The 2026 targets, raised on September 17, were confirmed. The stock thus loses ground despite more dynamic activity, with the gross margin being the declining element of this publication.
